...
首页> 外文期刊>Haematologica >Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia | Haematologica
【24h】

Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia | Haematologica

机译:特定的分子突变模式描述了慢性中性粒细胞白血病,非典型性慢性粒细胞性白血病和慢性粒细胞性白血病血液学

获取原文
           

摘要

Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare entities grouped into the World Health Organisation (WHO) categories myeloproliferative and myelodysplastic/myeloproliferative neoplasms (MPN and MDS/MPN overlap), respectively. According to the WHO 2008 classification,1 both entities are characterized by leukocytosis and a hypercellular bone marrow, predominantly consisting of granulocytic cells.Chronic neutrophilic leukemia is diagnosed by the expansion of neutrophils in the peripheral blood, the exclusion of an elevated blast count, and hepatosplenomegaly. In contrast to other MPNs, before 2013, no molecular marker was known to prove clonality or could shed light on the molecular nature of the disease. Therefore, CNL had been diagnosed by a number of exclusion criteria eliminating evidence for other neoplasms or myelodysplastic syndromes.Atypical CML is diagnosed by a similar approach, since diagnosis according to WHO has featured an increased number of neutrophil precursors, a defined threshold of blasts and monocytes, and dysplasia in the granulocytic lineage. A distinctive feature for differential diagnosis of CNL and aCML is the proportion of immature neutrophils (≥10% in aCML and <10% in CNL). As in CNL, other neoplasms and myelodysplastic syndromes should be excluded.In addition, also chronic myelomonocytic leukemia (CMML) shares several of these characteristics and, therefore, needs to be discriminated from the other two entities, especially by the absolute number of monocytes for clinical decision making.In the last three years, important markers have been identified for the diagnosis and differential diagnosis in these entities. ASXL1, SRSF2, and TET2 were found to be frequently mutated in CMML.2,3 SETBP1 was identified to be frequently mutated in aCML, which was shown to co-occur frequently with mutations in ASXL1 and CBL.4,5 CSF3R mutations were found to associate with CNL and aCML.6,7In Philadelphia negative MPNs, cytogenetic abnormalities occur, but the frequency differs and no specific abnormality has been defined in the different entities so far.8 Therefore, the aim of our study was to determine the frequencies of the new armamentarium of genes, i.e. ASXL1, CBL, CSF3R, SETBP1, SRSF2, and TET2 mutations in CNL, aCML, and CMML, to help guide the diagnosis and clinical decisions of these three, in part overlapping, entities. A total of 218 patients were diagnosed according to the WHO 2008 criteria, including 14 cases with CNL, 58 with aCML, and 146 with CMML (for more clinical details see Online Supplementary Table S1). Cytogenetics was available in 211 (97%) cases. In all cases, BCR-ABL1 was excluded by RT-PCR and/or FISH, and JAK2V617F mutation was analyzed by melting curve analyses, as were JAK2 exon 12 and MPL mutations in JAK2wild-type (wt) patients. CALR mutations were analyzed in JAK2wt CNL and aCML patients by Sanger sequencing. Presence of PDGFR-rearrangements was excluded in CNL by expression analyses of PDGFRA and PDGFRB. In all patients the mutational hot spot regions of ASXL1, CBL, CSF3R, SETBP1, and SRSF2 were analyzed by Sanger sequencing. The complete coding region of TET2 was analyzed by next generation sequencing in 217 of 218 cases. For more details see Online Supplementary Appendix.Cytogenetic aberrations were detected in 54 of 211 cases (26%); the most frequent were trisomie 8 (n=14), deletion of the Y chromosome (n=7), del(20q) (n=3), and i(17)(q10) (n=3). However, there was no association to one of these entities.Mutational analyses showed that ASXL1 was frequently mutated in all three diseases, resulting in mutation frequencies of 57% in CNL (8 of 14), 66% in aCML (38 of 58), and 45% in CMML (66 of 146), respectively (Figures 1 and 2). A similar frequency of ASXL1 mutations has previously been published in CMML.9 However, the frequency in aCML was higher than the 23% reported by Piazza et al.5 This finding of frequent appearance in CNL was su
机译:慢性中性粒细胞白血病(CNL)和非典型慢性粒细胞性白血病(aCML)是分别归入世界卫生组织(WHO)类别的骨髓增生性肿瘤和骨髓增生异常/骨髓增生性肿瘤(MPN和MDS / MPN重叠)的罕见实体。根据WHO 2008分类标准,这两个实体均具有白细胞增多症和主要由粒细胞组成的高细胞骨髓的特征。慢性嗜中性粒细胞白血病通过外周血中性粒细胞的扩增,排除的胚泡计数增加和肝脾肿大。与其他MPN相比,2013年之前,尚无分子标记可以证明克隆性或可以阐明该疾病的分子性质。因此,已经通过许多排除标准对CNL进行了诊断,排除了其他肿瘤或骨髓增生异常综合症的证据。非典型CML可以通过类似的方法进行诊断,因为根据WHO的诊断具有中性粒细胞前体的数量增加,确定的胚芽阈和单核细胞和粒细胞谱系的发育异常。 CNL和aCML鉴别诊断的显着特征是未成熟的中性粒细胞比例(aCML≥10%,CNL <10%)。与CNL一样,其他肿瘤和骨髓增生异常综合征也应排除在外。此外,慢性粒细胞性单核细胞白血病(CMML)具有这些特征中的几个特征,因此需要与其他两个实体区分开,特别是根据单核细胞的绝对数量临床决策。在过去三年中,已经为这些实体的诊断和鉴别诊断确定了重要的标志物。在CMML中发现ASXL1,SRSF2和TET2经常发生突变2.,3在aCML中发现SETBP1经常发生突变,这表明它与ASXL1和CBL中的突变经常同时发生.4,5发现了CSF3R突变与CNL和aCML相关[6,7]。在费城阴性MPN中,发生细胞遗传学异常,但频率不同,到目前为止,尚未在不同实体中定义特异性异常。8因此,本研究的目的是确定新的武器库,即CNL,aCML和CMML中的ASXL1,CBL,CSF3R,SETBP1,SRSF2和TET2突变基因,有助于指导这三个部分重叠的实体的诊断和临床决策。根据WHO 2008年标准,总共诊断出218例患者,包括14例CNL,58例aCML和146例CMML(更多临床信息,请参见在线补充表S1)。细胞遗传学可用于211(97%)病例。在所有情况下,RT-PCR和/或FISH均排除BCR-ABL1,并通过熔解曲线分析对JAK2V617F突变进行了分析,JAK2wild型(wt)患者的JAK2外显子12和MPL突变也是如此。通过Sanger测序分析了JAK2wt CNL和aCML患者的CALR突变。通过PDGFRA和PDGFRB的表达分析,CNL中排除了PDGFR重排的存在。在所有患者中,通过Sanger测序分析了ASXL1,CBL,CSF3R,SETBP1和SRSF2的突变热点区域。通过下一代测序分析了218例病例中的217例,分析了TET2的完整编码区。 211例病例中有54例(26%)检测到细胞遗传学异常。最常见的是三体性8(n = 14),Y染色体缺失(n = 7),del(20q)(n = 3)和i(17)(q10)(n = 3)。但是,与这些实体中的任何一个都没有关联。突变分析显示,ASXL1在所有三种疾病中都经常发生突变,导致CNL中的突变频率为57%(14个中的8个),aCML中66%的突变频率(58个中的38个) )和CMML中的45%(146个中的66个)(图1和2)。以前在CMML中已经发表了类似频率的ASXL1突变。9但是,aCML中的频率高于Piazza等人[5]报道的23%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号